GSK and Genmab seek FDA approval for ofatumumab combination therapy for CLL first-line treatment « New Drug Approvals

GSK and Genmab seek FDA approval for ofatumumab combination therapy for CLL first-line treatment « New Drug Approvals:

'via Blog this'